AMRN

Vascepa

Cardiovascular disease (triglyceride lowering)

Approved (Quarterly Sales)

Exp Date

Q2 2020

Amp Volatility Score

Catalyst Info & Data Links

Catalyst Events

  • Quarterly Vascepa revenue 

Revenue

Prior Guidance

  • Q1 investor presentation - 2020 guidance

▪ Net total revenue projected to be between $650M and $700M

[Amp believes $150M in Q1 '20 given prior Q1 are low

 

Prior Data Links:

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon